Claims

1. A solid pharmaceutical ~~composition~~ dosage form comprising a pharmaceutical composition which comprises a compound of the formula (I.9),



(I.9)

wherein the particle size distribution ~~in~~ of said ~~composition~~ compound of the formula (I.9) is 1μm ≤ X90 < 200 μm, and wherein said compound of the formula (I.9) represents 2.0 to ~~25~~15% ~~or less~~ of the weight of said composition, and wherein the amount of the compound of the formula (I.9) in said pharmaceutical dosage form is 10 or 25 mg.

2. The pharmaceutical ~~composition~~ dosage form according to claim 1, wherein the particle size distribution of the compound (I.9) in said pharmaceutical composition is 5 μm ≤ X90 ≤ 150 μm.

3. The pharmaceutical ~~composition~~ dosage form according to claim 1, wherein the particle size distribution of the compound (I.9) in said pharmaceutical composition is X90 ≤ 150 μm, 5 μm ≤ X50 ≤ 50 μm and X10 ≥ 0.5 μm.

~~4. The pharmaceutical composition according to any one of the claims 1 to 3, wherein said compound of the formula (I.9) represents 1.0 % to 20% of the weight of said composition.~~

~~5. The pharmaceutical composition according to claim 4, wherein said compound of the formula (I.9) represents 2.0 to 15% of the weight of said composition.~~

~~6~~4. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to ~~5~~3, wherein said pharmaceutical composition comprises the crystalline form (I.9X) of said compound of the formula (I.9).

~~7~~5. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to ~~6~~4, wherein said pharmaceutical composition comprises a disintegrant and a binder, wherein the ratio of said disintegrant to said binder is between 1.5 : 3.5 and 1 : 1

(weight/weight).

~~8~~6. The pharmaceutical ~~composition~~ dosage form according to ~~any one of~~ claims ~~1 to 7~~5, wherein at least 99% of the particles of said binder (by weight) are 250 µm or smaller.

7. The pharmaceutical dosage form according to claim 5 or 6 wherein the binder is hydroxypropyl cellulose and/or microcrystalline cellulose.

8. The pharmaceutical dosage form according to claim 5, 6 or 7 wherein the disintegrant is croscarmellose sodium.

9. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to 8, wherein said pharmaceutical composition is obtained by high shear wet granulation, wherein said composition further ~~comprising~~ comprises a diluent, wherein 5 - 20% (by weight) of said diluent is added to said composition as a dry add after said wet granulation.

10. The pharmaceutical dosage form ~~composition~~ according to any one of claims 1 to 9, wherein said composition comprises:

	Amount (% by weight)
the compound of the formula (I.9)	0.5 – 25
one or more diluents	65 - 93
one or more binders	1– 5
one or more disintegrants	1 – 4
optionally one or more additional additives	ad 100 %

11. The pharmaceutical ~~composition~~ dosage form according to ~~any one of~~ claims ~~1~~ 9 ~~to~~ or 10 wherein the diluent is lactose monohydrate and/or microcrystalline cellulose.

~~12. The pharmaceutical composition according to any one of claims 1 to 11 wherein the binder is hydroxypropyl cellulose and/or microcrystalline cellulose.~~

~~13. The pharmaceutical composition according to any one of claims 1 to 12 wherein the disintegrant is croscarmellose sodium.~~

~~14~~12. The pharmaceutical dosage form ~~composition~~ according to any one of claims 1 to ~~13~~11, further comprising one or more lubricants.

~~15~~13. The pharmaceutical ~~composition~~ dosage form according to claim ~~14~~ 12 wherein the lubricant is magnesium stearate.

~~16~~14. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to ~~15~~13, further comprising one or more glidants.

~~17~~15. The pharmaceutical ~~composition~~ dosage form according to claim ~~16~~ 14 wherein the glidant is colloidal silicon dioxide or talc.

~~18~~16. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to ~~17~~15, further comprising one or more film coats.

~~19~~17. The pharmaceutical ~~composition~~ dosage form according to any one of claims 1 to ~~18~~16, wherein said pharmaceutical composition comprises:

	Amount (% by weight)
Active ingredient	0.5 – 25
Lactose monohydrate	35 - 70
Microcrystalline cellulose	20 – 40
Hydroxypropyl cellulose	1 – 5
Croscarmellose sodium	1 – 3
Optionally additional additives	ad 100 %

~~20. A pharmaceutical dosage form comprising a pharmaceutical composition according to any one of claims 1 to 19.~~

~~21~~18. The pharmaceutical dosage form according to any one of claims ~~20~~1 to 17, wherein said dosage form is a tablet.

~~22. The pharmaceutical dosage form according to claim 20 or 21, comprising 5 to 25 mg of the compound of the formula (I.9) according to claim 1.~~

~~23. The pharmaceutical dosage form according to claim 22, comprising 10 or 25 mg of the compound of the formula (I.9) according to claim 1.~~

~~24~~19. Use of ~~a pharmaceutical composition or~~ a pharmaceutical dosage form according to any one of the claims 1 to ~~23~~18 ~~for~~ in the manufacture of a medicament for treating a metabolic disorder selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, overweight, obesity and metabolic syndrome.